Company profile
Eikon Therapeutics, Inc.
NASDAQ:EIKNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Resiquimod Sulfate | phase2 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06253130 | phase1_2 | recruiting | 2023-12-11 | 2027-06-01 | Eikon Therapeutics | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors |
| NCT06246110 | phase2 | active_not_recruiting | 2024-02-06 | 2026-12-01 | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
| NCT07365319 | phase2_3 | recruiting | 2026-06-15 | 2035-12-31 | Eikon Therapeutics | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. |
| NCT06907043 | phase1_2 | recruiting | 2025-04-30 | 2028-12-01 | Eikon Therapeutics | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. |
| NCT03486301 | phase1 | completed | 2018-02-15 | 2024-03-31 | Eikon Therapeutics | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab |
FDA applications (0)
No records yet.